ZA202309225B - Immunogenic fusion protein - Google Patents
Immunogenic fusion proteinInfo
- Publication number
- ZA202309225B ZA202309225B ZA2023/09225A ZA202309225A ZA202309225B ZA 202309225 B ZA202309225 B ZA 202309225B ZA 2023/09225 A ZA2023/09225 A ZA 2023/09225A ZA 202309225 A ZA202309225 A ZA 202309225A ZA 202309225 B ZA202309225 B ZA 202309225B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acid
- amino acids
- acid sequence
- fusion protein
- immunogenic fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 241000193990 Streptococcus sp. 'group B' Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21165674.9A EP4066854A1 (en) | 2021-03-29 | 2021-03-29 | Immunogenic fusion protein |
| PCT/EP2022/058309 WO2022207657A1 (en) | 2021-03-29 | 2022-03-29 | Immunogenic fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309225B true ZA202309225B (en) | 2025-03-26 |
Family
ID=75277909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09225A ZA202309225B (en) | 2021-03-29 | 2023-10-02 | Immunogenic fusion protein |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240173394A1 (https=) |
| EP (2) | EP4066854A1 (https=) |
| JP (1) | JP2024512722A (https=) |
| KR (1) | KR20230163500A (https=) |
| CN (1) | CN117120081A (https=) |
| AU (1) | AU2022248869A1 (https=) |
| BR (1) | BR112023019757A2 (https=) |
| CA (1) | CA3212987A1 (https=) |
| IL (1) | IL307256A (https=) |
| MX (1) | MX2023011502A (https=) |
| WO (1) | WO2022207657A1 (https=) |
| ZA (1) | ZA202309225B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4553166A1 (en) | 2023-11-07 | 2025-05-14 | MinervaX ApS | Method for preparing a sample for analysis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107458A0 (en) | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
| HU217582B (hu) | 1993-03-19 | 2000-02-28 | Gunnar Lindahl | Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény |
| US6426074B1 (en) | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
| SI2144924T1 (sl) * | 2007-04-16 | 2016-12-30 | Minervax Aps | Cepivo s fuzijskimi beljakovinami |
| CN108135992A (zh) * | 2015-10-21 | 2018-06-08 | 米纳瓦克斯有限责任公司 | 免疫原性融合蛋白 |
| US10888610B2 (en) * | 2015-12-30 | 2021-01-12 | Minerv Ax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
-
2021
- 2021-03-29 EP EP21165674.9A patent/EP4066854A1/en not_active Withdrawn
-
2022
- 2022-03-29 JP JP2023560549A patent/JP2024512722A/ja active Pending
- 2022-03-29 CN CN202280027427.3A patent/CN117120081A/zh active Pending
- 2022-03-29 BR BR112023019757A patent/BR112023019757A2/pt unknown
- 2022-03-29 KR KR1020237037124A patent/KR20230163500A/ko active Pending
- 2022-03-29 WO PCT/EP2022/058309 patent/WO2022207657A1/en not_active Ceased
- 2022-03-29 US US18/284,513 patent/US20240173394A1/en active Pending
- 2022-03-29 AU AU2022248869A patent/AU2022248869A1/en active Pending
- 2022-03-29 MX MX2023011502A patent/MX2023011502A/es unknown
- 2022-03-29 EP EP22713429.3A patent/EP4313134A1/en active Pending
- 2022-03-29 CA CA3212987A patent/CA3212987A1/en active Pending
- 2022-03-29 IL IL307256A patent/IL307256A/en unknown
-
2023
- 2023-10-02 ZA ZA2023/09225A patent/ZA202309225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4313134A1 (en) | 2024-02-07 |
| MX2023011502A (es) | 2023-10-19 |
| CA3212987A1 (en) | 2022-10-06 |
| AU2022248869A9 (en) | 2023-11-09 |
| US20240173394A1 (en) | 2024-05-30 |
| JP2024512722A (ja) | 2024-03-19 |
| AU2022248869A1 (en) | 2023-10-26 |
| BR112023019757A2 (pt) | 2023-10-31 |
| KR20230163500A (ko) | 2023-11-30 |
| EP4066854A1 (en) | 2022-10-05 |
| IL307256A (en) | 2023-11-01 |
| CN117120081A (zh) | 2023-11-24 |
| WO2022207657A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200870176A1 (ru) | НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE) | |
| ATE482714T1 (de) | Modifizierter hitzeschockprotein-antigenpeptid- komplex | |
| CN103160530B (zh) | 一种融合基因及其应用 | |
| JPH04506005A (ja) | 破傷風トキシンフラグメントｃの発現 | |
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| ZA202309225B (en) | Immunogenic fusion protein | |
| CN107488234B (zh) | 禽腺病毒Hexon与鸡传染性法氏囊病病毒VP2融合抗原、亚单位疫苗及其制备方法 | |
| CN102333539B (zh) | 重组禽传染性鼻炎疫苗及其制备方法 | |
| DE60235021D1 (de) | Rekombinante, 56 bzw. 82 kda grosse antigene aus gametozyten von eimeria maxima codierende nukleinsäuren und ihre verwendungen | |
| MX2025013140A (es) | Composiciones para el uso en el tratamiento del acne | |
| CN102277374A (zh) | 一种鸡传染性法氏囊病基因工程亚单位疫苗的制备和应用 | |
| RU2012149036A (ru) | Векторы парапоксвируса, содержащие антиген вируса бешенства | |
| CN118420773A (zh) | 一种重组蛋白纳米颗粒及其制备方法和在制备广谱抗流感病毒疫苗中的应用 | |
| JPWO2005083072A1 (ja) | 大腸菌における豚丹毒菌表層防御抗原変異体の製造方法 | |
| JP2024512722A5 (https=) | ||
| EP0404576A2 (en) | Recombinant avipoxvirus | |
| WO2022003719A3 (en) | POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF | |
| CN108359682A (zh) | 一种具有免疫保护作用的迟缓爱德华菌外膜蛋白PagC | |
| CN107974458A (zh) | 表达猪丹毒杆菌重组蛋白GAPDH的基因gapdh及其重组大肠杆菌与应用 | |
| CN103524624B (zh) | 新城疫病毒和鸭圆环病毒融合蛋白及其编码基因与应用 | |
| CN103145854B (zh) | 重组Tβ4-BP5融合肽、基因、工程菌及应用 | |
| WO2010097977A1 (ja) | 豚丹毒・豚マイコプラズマ肺炎経口投与型多価ワクチン | |
| JP3532510B2 (ja) | 組換え豚丹毒菌防御抗原の回収精製法 | |
| CN100409900C (zh) | 葡萄球菌肠毒素a基因及其编码蛋白的新用途 | |
| EP0542895B1 (en) | Cross-reactive influenza a immunization |